Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROSALYN ELIZABETH GEORGE

Allopathic & Osteopathic Physicians Dermatology

NPI
1639391931
CMS profile
1206960
Location
WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$71,529.69

159 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 4; records 151–159 of 159 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROSALYN ELIZABETH GEORGE

NPI 1639391931 · CMS profile ID 1206960

Allopathic & Osteopathic Physicians / Dermatology

WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–159 of 159 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639391931?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROSALYN ELIZABETH GEORGE, NPI 1639391931, CMS profile ID 1206960. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–159 of 159 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639391931?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ROSALYN ELIZABETH GEORGE, NPI 1639391931, CMS profile ID 1206960. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–159 of 159 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639391931?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ROSALYN ELIZABETH GEORGE, NPI 1639391931, CMS profile ID 1206960, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–159 of 159 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1639391931?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

159 matching records · $71,529.69 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 159 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–159 of 159.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $19.9302/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659692691 CMS
PFIZER INC. $11.4901/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673738117 CMS
UCB, Inc. $294.5001/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688236081 CMS
UCB, Inc. $60.0001/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688236083 CMS
Allergan Inc. $18.1801/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670402479 CMS
Regeneron Healthcare Solutions, Inc. $18.0801/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673382477 CMS
Allergan Inc. $61.3101/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670402473 CMS
Sun Pharmaceutical Industries Inc. $19.3101/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704629631 CMS
Merz North America, Inc. $154.7201/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 689376473 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $71,529.69 159
PY2020 $10,717.18 34
PY2021 $43,081.20 90
PY2022 $65,332.86 134
PY2023 $72,746.09 140
PY2024 $22,602.03 105
PY2025 $59,990.31 125

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $847,579.99 72
PY2024 Recipient $2,597.72 4
PY2024 Principal investigator $364,264.30 63
PY2023 Principal investigator $437,964.82 54
PY2022 Principal investigator $2,080,807.39 135
PY2021 Principal investigator $1,007,808.02 76
PY2020 Recipient $224.42 1
PY2020 Principal investigator $867,911.34 90
PY2019 Principal investigator $592,366.00 58

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

72 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $2,177.82 12/31/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 1 Study to Evaluate the Safety and Efficacy of Co-administration of AGN-151586 and BOTOX in Subjects for Treatment of Glabellar Lines (GL) No dispute reported 06/30/2026 1202534315
Principal investigator 1 ABBVIE INC. $916.68 12/31/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study No dispute reported 06/30/2026 1202534317
Principal investigator 1 Janssen Research & Development, LLC $2,329.00 12/25/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415929
Principal investigator 1 ABBVIE INC. $104.00 12/24/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A multicenter, double-blind, randomized, parallel-group, controlled study to evaluate the safety and effectiveness of ELAPR002f injectable gel in adult participants with atrophic acne scars No dispute reported 06/30/2026 1202532004
Principal investigator 1 ABBVIE INC. $3,300.00 12/18/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202531156
Principal investigator 1 Janssen Research & Development, LLC $3,430.00 12/01/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415971
Principal investigator 1 Janssen Research & Development, LLC $6,735.00 12/01/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175416081
Principal investigator 1 ABBVIE INC. $127.40 11/26/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202525662
Principal investigator 1 ABBVIE INC. $468.00 11/13/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A multicenter, double-blind, randomized, parallel-group, controlled study to evaluate the safety and effectiveness of ELAPR002f injectable gel in adult participants with atrophic acne scars No dispute reported 06/30/2026 1202524249
Principal investigator 1 ABBVIE INC. $3,520.90 11/13/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202524251
Principal investigator 1 ABBVIE INC. $25,250.30 11/13/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202524265
Principal investigator 1 ABBVIE INC. $1,500.00 11/12/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A multicenter, double-blind, randomized, parallel-group, controlled study to evaluate the safety and effectiveness of ELAPR002f injectable gel in adult participants with atrophic acne scars No dispute reported 06/30/2026 1202523891
Principal investigator 1 ABBVIE INC. $3,500.00 11/12/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A multicenter, double-blind, randomized, parallel-group, controlled study to evaluate the safety and effectiveness of ELAPR002f injectable gel in adult participants with atrophic acne scars No dispute reported 06/30/2026 1202523897
Principal investigator 1 ABBVIE INC. $837.20 11/05/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202522745
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61.29 10/30/2025 Non-covered Recipient Entity
Wilmington Dermatology Center
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235991646
Principal investigator 1 Janssen Research & Development, LLC $2,931.00 10/24/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415995
Principal investigator 1 ABBVIE INC. $48,575.30 10/16/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202517123
Principal investigator 1 ABBVIE INC. $3,520.90 10/15/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202516857
Principal investigator 1 ABBVIE INC. $37,648.60 09/19/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202511648
Principal investigator 1 ABBVIE INC. $3,480.60 09/18/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202511442
Principal investigator 1 Janssen Research & Development, LLC $3,430.00 09/08/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415923
Principal investigator 1 Janssen Research & Development, LLC $6,066.00 09/04/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175416063
Principal investigator 1 Amgen Inc. $2,300.00 08/23/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) No dispute reported 06/30/2026 1246652018
Principal investigator 1 Janssen Research & Development, LLC $362.00 08/22/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415952
Principal investigator 1 Janssen Research & Development, LLC $1,116.00 08/22/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415989
Principal investigator 1 ABBVIE INC. $1,994.00 08/20/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202505233
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,416.32 08/18/2025 Non-covered Recipient Entity
Wilmington Dermatology Center
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235991648
Principal investigator 1 ABBVIE INC. $166,275.06 08/14/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202504781
Principal investigator 1 ABBVIE INC. $5,220.90 08/14/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202504783
Principal investigator 1 Janssen Research & Development, LLC $69.15 08/11/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175416020
Principal investigator 1 ABBVIE INC. $3,315.00 07/31/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202500572
Principal investigator 1 ABBVIE INC. $530.40 07/31/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202500582
Principal investigator 1 ABBVIE INC. $320.00 07/30/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202500442
Principal investigator 1 Janssen Research & Development, LLC $4,053.00 07/28/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415946
Principal investigator 1 Janssen Research & Development, LLC $1,457.00 07/28/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175416075
Principal investigator 1 Janssen Research & Development, LLC $750.00 07/25/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175416008
Principal investigator 1 Janssen Research & Development, LLC $362.00 07/25/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175416013
Principal investigator 1 Janssen Research & Development, LLC $2,473.00 07/21/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175416047
Principal investigator 1 ABBVIE INC. $1,460.00 07/18/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202498906
Principal investigator 1 ABBVIE INC. $154,984.90 07/17/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202498552
Principal investigator 1 ABBVIE INC. $7,082.10 07/16/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202498352
Principal investigator 1 Janssen Research & Development, LLC $1,750.00 07/04/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415958
Principal investigator 1 Janssen Research & Development, LLC $932.00 07/04/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175416002
Principal investigator 1 Janssen Research & Development, LLC $2,685.00 06/23/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175416057
Principal investigator 1 ABBVIE INC. $102,016.70 06/17/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202491793
Principal investigator 1 ABBVIE INC. $10,482.10 06/12/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202491219
Principal investigator 1 Janssen Research & Development, LLC $25.55 06/09/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415933
Principal investigator 1 ABBVIE INC. $93.60 05/28/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202486505
Principal investigator 1 ABBVIE INC. $234.38 05/28/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202486507
Principal investigator 1 Janssen Research & Development, LLC $2,473.00 05/26/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175415964
Principal investigator 1 Janssen Research & Development, LLC $4,371.00 05/22/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175415976
Principal investigator 1 ABBVIE INC. $14,227.90 05/16/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202485351
Principal investigator 1 Janssen Research & Development, LLC $10,918.00 05/09/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175416034
Principal investigator 1 Janssen Research & Development, LLC $116.93 05/09/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175416040
Principal investigator 1 Janssen Research & Development, LLC $2,217.00 04/28/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175416026
Principal investigator 1 Amgen Inc. $27,160.00 04/24/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246652021
Principal investigator 1 ABBVIE INC. $10,530.20 04/16/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202476885
Principal investigator 1 Janssen Research & Development, LLC $2,217.00 03/27/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175416052
Principal investigator 1 ABBVIE INC. $12,487.60 03/13/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202463053
Principal investigator 1 Janssen Research & Development, LLC $9,620.00 03/03/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175416070
Principal investigator 1 ABBVIE INC. $14,276.00 02/13/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202450932
Principal investigator 1 Janssen Research & Development, LLC $153.77 02/03/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175415940
Principal investigator 1 ABBVIE INC. $8,500.00 01/28/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
M25-207 - A Study to Assess the Adverse Events of Intramuscular Injections of AGN-151586 and OnabotulinumtoxinA in Adult Participants for the Change of Glabellar Lines (GL) No dispute reported 06/30/2026 1202441487
Principal investigator 1 ABBVIE INC. $17,723.20 01/28/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202441491
Principal investigator 1 ABBVIE INC. $15,942.60 01/28/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202441495
Principal investigator 1 ABBVIE INC. $12,664.40 01/28/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202441499
Principal investigator 1 ABBVIE INC. $200.00 01/28/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202441504
Principal investigator 1 ABBVIE INC. $627.00 01/28/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202441511
Principal investigator 1 ABBVIE INC. $610.00 01/28/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
M21-416 - BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence A Phase 3 Multicenter Randomized Double-Blind Placebo-Controlled Study No dispute reported 06/30/2026 1202441515
Principal investigator 1 Janssen Research & Development, LLC $4,103.00 01/24/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment No dispute reported 06/30/2026 1175415982
Principal investigator 1 Eli Lilly and Company $22,958.73 01/23/2025 Non-covered Recipient Entity
WDC COSMETIC AND RESEARCH PLLC
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187893878
Principal investigator 1 Amgen Inc. $17,812.51 01/06/2025 Non-covered Recipient Entity
WILMINGTON DERMATOLOGY CENTER
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) No dispute reported 06/30/2026 1246652270